Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
Open Access
- 3 October 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 86, 106-114
- https://doi.org/10.1016/j.ejca.2017.09.003
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Metformin inhibits melanoma development through autophagy and apoptosis mechanismsCell Death & Disease, 2011
- Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1Cancer Research, 2011
- Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LARCell Death & Disease, 2011
- SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS productionOncogene, 2011
- Metformin Prevents Tobacco Carcinogen–Induced Lung TumorigenesisCancer Prevention Research, 2010
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver diseaseLiver International, 2010
- Insulin, insulin-like growth factors and neoplasiaBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicityOncogene, 2006